Small molecule · Inhibitor of BCR-ABL1 fusion protein tyrosine kinase · developed by Enliven Therapeutics
Relcobatinib is an orally administered, selective inhibitor that binds the ATP-binding site of the kinase domain of activated BCR-ABL1 fusion protein, including wild-type and the T315I mutant forms. It is being studied in chronic phase chronic myelogenous leukemia (CML).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06787144 | Phase 1 | CML (Chronic Myelogenous Leukemia) | Recruiting | ELVN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Phase CMLCML (Chronic Myelogenous Leukemia)
Updated Oct 11, 2026. Something wrong or missing? Report it on the ELVN page.
See ELVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ELVN catalysts and pipeline →